Monte Rosa Therapeutics Presents Preclinical Data at ACR Con

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Diego , California , United States , Boston , Massachusetts , Marisa Peluso , Monte Rosa , Cory Tromblee , Bowen Wallace , Monta Rosa Qu , Andrew Funderburk , Monte Rosa Therapeutics Inc , Exchange Commission On , Nasdaq , American College Of Rheumatology , Rosa Therapeutics Presents Preclinical Data , Molecular Glue Degrader , Treat Immunological , New Drug , Poster Session , Rosa Therapeutics , American College , Convergence Annual Meeting , Chief Scientific Officer , Directed Molecular Glue Degrader , Reduces Joint Inflammation , T Andb Cell , Engineered Elimination , Private Securities Litigation Reform Act , Annual Report , Exchange Commission ,